In a wide-ranging interview with USA TODAY, Melinda Gates talks about the goal of her new donation, global health, education and finding hope.
Author: Karen Weintraub, USA TODAY
Second dose of COVID vaccine from Pfizer or Moderna is needed, but timing doesn’t have to be exact, says government vaccine developer
Getting both shots of COVID vaccine designed as two doses is important but timing doesn’t have to be exact, Operation Warp Speed’s Moncef Slaoui says.
‘Very inconsistent’: 2 allergic reactions in the UK to COVID-19 vaccine puzzle researchers
British regulators advised people with severe allergies not to take Pfizer vaccine. One US researcher says that would be a ‘showstopper’ here.
‘No surprises’: 53-page FDA report reinforces safety and effectiveness of Pfizer’s COVID-19 vaccine candidate
FDA summary on Pfizer’s candidate COVID-19 vaccine supports earlier findings that it is safe and will prevent 95% of people from becoming sick.
Deliver a safe, effective COVID-19 vaccine in less than a year? Impossible. Meet Moncef Slaoui.
As science adviser of Operation Warp Speed, the veteran pharmaceutical executive helped usher a coronavirus vaccine to the US market in record time.
Moderna becomes second company to request emergency FDA authorization for COVID-19 vaccine candidate
Moderna will be the second coronavirus vaccine maker to request authorization from the government after similarly positive trial results for Pfizer.
Moderna’s candidate COVID-19 vaccine looks to protect 94.5% of those who get it, trial shows
Moderna’s candidate COVID-19 vaccine is even more effective that Pfizer’s, trial results show, a “light at the end of the tunnel” for the pandemic.
Infected again or endless COVID? How the ‘reinfection phenomenon’ could impact vaccines, herd immunity and human behavior.
Can you get it again? Scientists are still investigating to find out how long the immune system can keep someone safe from COVID-19 after infection.
Pfizer’s COVID vaccine candidate shown to be 90% effective in early findings
Pfizer is the first drug company to release data from a large, Phase 3 trial, designed to show both effectiveness and safety.
COVID-19 vaccine should be ready for most vulnerable late this year, for everyone by spring, HHS Secretary Alex Azar says
During a rare CDC public briefing, HHS Secretary Alex Azar on Wednesday outlined a timeline for the COVID-19 vaccine and pledged it would be safe.